Employees: 03 (2023.0)Legal category: Société à responsabilité limitée (sans autre indication)Size: PMECreation date: 2015-10-21 (10 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: LA SEGUINIERE (49280), Maine-et-Loire
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
EURL PHARMACIE BEAUVAIS : revenue, balance sheet and financial ratios
EURL PHARMACIE BEAUVAIS is a French company
founded 10 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in LA SEGUINIERE (49280),
this company of category PME
shows in 2022 a revenue of 2.4 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - EURL PHARMACIE BEAUVAIS (SIREN 814239323)
Indicator
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
N/C
2 405 234 €
N/C
N/C
N/C
N/C
N/C
N/C
Net income
207 216 €
159 432 €
203 161 €
186 583 €
161 188 €
190 609 €
161 128 €
161 704 €
52 648 €
EBITDA
N/C
N/C
278 177 €
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
8.4%
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, EURL PHARMACIE BEAUVAIS generates positive net income of 207 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 53 k€ -> 207 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
207 216 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 35%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 67%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
34.868%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
66.635%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Debt ratio
0.0
606.141
333.21
193.79
134.58
95.169
68.567
48.756
34.868
Financial autonomy
4.112
12.704
21.452
31.194
39.008
46.57
54.278
61.614
66.635
Repayment capacity
None
None
None
None
None
None
3.975
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
8.154%
None%
None%
Sector positioning
Debt ratio
34.872024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Good-11 pts over 3 years
In 2024, the debt ratio of EURL PHARMACIE BEAUVAIS (34.87) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
66.64%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Good+12 pts over 3 years
In 2024, the financial autonomy of EURL PHARMACIE BEAUVAIS (66.6%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
3.98 years2022
2022
Q1: 1.29 years
Med: 3.55 years
Q3: 6.63 years
Average
In 2022, the repayment capacity of EURL PHARMACIE BEAUVAIS (3.98) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 380.89. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
286.717
224.868
343.7
320.455
339.37
361.295
420.424
430.628
380.89
Interest coverage
None
None
None
None
None
None
2.761
None
None
Sector positioning
Liquidity ratio
380.892024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Excellent
In 2024, the liquidity ratio of EURL PHARMACIE BEAUVAIS (380.89) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Interest coverage
2.76x2022
2022
Q1: 0.74x
Med: 2.5x
Q3: 5.15x
Good
In 2022, the interest coverage of EURL PHARMACIE BEAUVAIS (2.8x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution EURL PHARMACIE BEAUVAIS
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Operating WCR
0 €
0 €
0 €
0 €
0 €
0 €
157 543 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
0
0
25
0
0
Customer payment term (days)
0
0
0
0
0
0
5
0
0
Supplier payment term (days)
0
0
0
0
0
0
25
0
0
Positioning of EURL PHARMACIE BEAUVAIS in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of EURL PHARMACIE BEAUVAIS is estimated at
2 892 888 €
(range 2 014 561€ - 4 327 926€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
2014k€2892k€4327k€
2 892 888 €Range: 2 014 561€ - 4 327 926€
NAF 5 année 2024
Valuation method used
Net Income Multiple
207 216 €
×
14.0x
=2 892 889 €
Range: 2 014 562€ - 4 327 927€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare EURL PHARMACIE BEAUVAIS with other companies in the same sector:
Frequently asked questions about EURL PHARMACIE BEAUVAIS
What is the revenue of EURL PHARMACIE BEAUVAIS ?
The revenue of EURL PHARMACIE BEAUVAIS in 2022 is 2.4 M€.
Is EURL PHARMACIE BEAUVAIS profitable?
Yes, EURL PHARMACIE BEAUVAIS generated a net profit of 207 k€ in 2024.
Where is the headquarters of EURL PHARMACIE BEAUVAIS ?
The headquarters of EURL PHARMACIE BEAUVAIS is located in LA SEGUINIERE (49280), in the department Maine-et-Loire.
Where to find the tax return of EURL PHARMACIE BEAUVAIS ?
The tax return of EURL PHARMACIE BEAUVAIS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does EURL PHARMACIE BEAUVAIS operate?
EURL PHARMACIE BEAUVAIS operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart